Why glucocorticosteroids should remain in the list of prohibited substances: A sports medicine viewpoint

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 19-24

  Pigozzi, Fabio ^a,b   Di Gianfrancesco, A ^a   Zorzoli, M ^c   Bachl, N ^d   Mc Donagh, D ^e   Cummiskey, J ^f   Di Luigi, L ^a   Pitsiladis, Y ^g   Borrione, P ^a,b  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b FIFA MEDICAL CENTRE OF EXCELLENCE   (Switzerland)

^c International Cycling Union   (Switzerland)

^d UNIVERSITY OF VIENNA   (Austria)

^e National University   (Norway)

^f IOC Medical Commission   (Ireland)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Abuse; Athletes; Doping; Glucocorticosteroids; Sports medicine

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID;

ADRENAL CORTEX INSUFFICIENCY; ALLERGIC REACTION; ALLERGIC RHINITIS; ANKYLOSING SPONDYLITIS; ASTHMA; BRAIN EDEMA; BRAIN TUMOR; BULLOUS DERMATITIS; BURSITIS; CONGENITAL HYPOPLASTIC ANEMIA; DERMATOMYOSITIS; DRUG RECEPTOR BINDING; EPICONDYLITIS; ERYTHEMA MULTIFORME; ERYTHROCYTE APLASIA; GOUT; HEMOLYTIC ANEMIA; HUMAN; LEUKEMIA; LOEFFLER PNEUMONIA; LUNG TUBERCULOSIS; LYMPHOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEPHROTIC SYNDROME; OSTEOARTHRITIS; POLYMYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SPORTS MEDICINE; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; DOPING; DRUG EFFECT; DRUG INDICATION; SIDE EFFECT;

EID: 84861473135     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500103     Document Type: Review

References (40)

1. Angeli A, Minetto M, Dovio A, Paccotti P. The overtraining syndrome in athletes: a stress-related disorder. J Endocrinol Invest 2004; 27:603-12. (Pubitemid 39255514)
2. Barnes PJ. Anti inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94:557-72. (Pubitemid 28269054)
3. Wehling M. Specific Non genomic actions of steroid hormones. Ann Rev Physiol 1997; 59:365-93. (Pubitemid 27142447)
4. Beato M, Truss M, Chavez S. Control of transcription by steroid hormones. Ann NY Acad Sci 1996; 784:93-123. (Pubitemid 26194758)
5. Charron J, Drouin J. Glucocorticoid inhibition of transcription from episomal proopiomelanocortin gene promoter. Proc Natl Acad Sci USA 1986; 83:8903-7. (Pubitemid 17223509)
6. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91:752-6. (Pubitemid 24041480)
7. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000; 55:603-13. (Pubitemid 30398277)
8. Moghadam AH, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8:473-9. (Pubitemid 34546749)
9. Rogoff JM, Stewart GN. The influence of adrenal extracts on the survival period of adrenalectomized dogs. Science 1927; 66:327.
10. Fineman EH. The use of suprarenal cortex extract in the treatment of bronchial asthma. J Allerg 1932; 4:182-90.
11. Carey RA, Harvey AM, Howard JE, Winkenwerder WL. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of chronic bronchial asthma. Bull John Hopkins Hosp 1950; 87:387-414.
12. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids. New Mechanisms for old drugs. N Engl J Med 2005; 353:1711-23.
13. Keith BD. Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 2008; 28:84-103.
14. Collomp K, Arlettaz A, Portier H, Lecoq AM, Le Panse B, Rieth N, De Ceaurriz J. Short-term glucocorticoid intake combined with intense training on performance and hormonal responses. Br J Sports Med 2008; 42:983-8.
15. Minetto M, Rainoldi A, Gazzoni M, et al. Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. Eur J Appl Physiol 2005; 93:679-86. (Pubitemid 40443788)
16. Duclos M, Gouarne C, Bonnemaison D. Acute and chronic effects of exercise on tissue sensitivity to glucocorticoids. J Appl Physiol 2003; 94:869-75. (Pubitemid 36231997)
17. Piazza PV, Rouge-Pont F, Deroche V, Maccari S, Simon H, Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci USA 1996; 93:8716-20. (Pubitemid 26269626)
18. Duclos M. Glucocorticoids: a doping agent? Endocrinol Metab Clin N Am 2010; 39:107-26.
19. Kuipers H, Van't Hullenaar GA, Pluim BM, Overbeek SE, De Hon O, Van Breda EJ, Van Loon LC. Four weeks' corticosteroid inhalation does not augment maximal power output in endurance athletes. Br J Sports Med 2008; 42:568-71.
20. Baume N, Steel G, Edwards T, Thorstensed E, Miller BF. No variation of physical performance and perceived exertion after adrenal gland stimulation by synthetic ACTH (Synacthen) in cyclists. Eur J Appl Physiol 2008; 104:589-600.
21. Le Panse B, Thomasson R, Jollin L, Lecoq AM, Amiot V, Rieth N, De Ceaurriz J, Collomp K. Short-term glucocorticoid intake improves exercise endurance in healthy recreationally trained women. Eur J Appl Physiol 2009; 107:437-43.
22. Thomasson R, Rieth N, Jollin L, Amiot V, Lasne F, Collomp K. Short-term glucocorticoid intake and metabolic responses during long-lasting exercise. Horm Metab Res 2011; 43:216-22.
23. Soetens E, De MK, Hueting JE. No influence of ACTH on maximal performance. Psychopharmacology 1995; 118:260-6.
24. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2007; 19:370-5. (Pubitemid 46884194)
25. Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 2009; 72(S):36-41.
26. Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann NY Acad Sci 2009; 1179:1-18.
27. Nussinovitch U, de Carvalho JF, Pereira RM, Shoenfeld Y. Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010; 16:3574-85.
28. Lin H, Casale TB. Treatment of allergic asthma. Am J Med 2002; 113(S):8-16.
29. Mori F, Barni S, Pucci N, Rossi ME, Orsi Battaglini C, Novembre E. Upper airways disease: role of corticosteroids. Int J Immunopathol Pharmacol 2010; 23:61-6.
30. Lavelle W, Demers Lavelle E, Lavelle L. Intra-Articular Injections. Anesthesiology Clin 2007; 25:853-62. (Pubitemid 350180666)
31. Brinks A, Koes BW, Volkers AC, Verhaar JA, Bierma-Zeinstra SM. Adverse effects of extraarticular corticosteroid injections: a systematic review. BMC Musculoskelet Disord 2010; 13:206-17.
32. Snibbe JC, Gambardella RA. Use of injections for osteoarthritis in joints and sports activity. Clin Sports Med 2005; 24:83-91. (Pubitemid 43073037)
33. Wittich CM, Ficalora RD, Mason TG, Beckman TJ. Musculoskeletal injection. Mayo Clin Proc 2009; 9:831-7.
34. Buckwalter JA. Current concepts review: pharmacological treatment of soft tissue injuries. J Bone Joint Surg Am 1995; 77:1902-14.
35. Fredberg L. Local corticosteroid injection in sport: review of literature and guidelines for treatment. Scand J Med Sei Sports 1997; 7:131-9.
36. Speed C.A. Injection therapies for soft-tissue disorders. Best Pract Res Clin Rheumatol 2007; 21:333-347.
37. Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 2010; 81:1400-33.
38. Brown A. Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med 1998; 15:89-95.
39. Ring J, Grosber M, Möhrenschlager M, Brockow K. Anaphylaxis: acute treatment and management. Chem Immunol Allergy 2010; 95:201-10.
40. Brown S, Blackman K, Heddle R. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Aust 2004; 16:120-4. (Pubitemid 38595820)